CR7795A - TETRALINOS AND INDANES SUBSTITUTES - Google Patents

TETRALINOS AND INDANES SUBSTITUTES

Info

Publication number
CR7795A
CR7795A CR7795A CR7795A CR7795A CR 7795 A CR7795 A CR 7795A CR 7795 A CR7795 A CR 7795A CR 7795 A CR7795 A CR 7795A CR 7795 A CR7795 A CR 7795A
Authority
CR
Costa Rica
Prior art keywords
tetralinos
indanes
substitutes
tetralin
modulators
Prior art date
Application number
CR7795A
Other languages
Spanish (es)
Inventor
Xiaoli Chen
Jay M Matthews
Jung Lee
Philip Rybczynski
Keith T Demarest
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR7795A publication Critical patent/CR7795A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C07C323/44—X or Y being nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención tiene como caracteristica compuestos de tetralina e indano, composiciones que los contienen y métodos de uso de los mismos como moduladores del PPAR alfa, para tratar o inhibir la progresión de por ejemplo la diabetes.The invention has as its characteristic tetralin and indane compounds, compositions containing them and methods of use thereof as modulators of PPAR alpha, to treat or inhibit the progression of, for example, diabetes.

CR7795A 2002-10-21 2005-04-18 TETRALINOS AND INDANES SUBSTITUTES CR7795A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41993502P 2002-10-21 2002-10-21
US49527003P 2003-08-15 2003-08-15

Publications (1)

Publication Number Publication Date
CR7795A true CR7795A (en) 2012-10-25

Family

ID=32179771

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7795A CR7795A (en) 2002-10-21 2005-04-18 TETRALINOS AND INDANES SUBSTITUTES

Country Status (17)

Country Link
EP (1) EP1569897A1 (en)
JP (1) JP2006503916A (en)
KR (1) KR20050055773A (en)
AU (1) AU2003277441B2 (en)
BR (1) BR0315596A (en)
CA (1) CA2502661A1 (en)
CR (1) CR7795A (en)
EA (1) EA009553B1 (en)
EG (1) EG24842A (en)
HR (1) HRP20050335A2 (en)
MX (1) MXPA05004191A (en)
NO (1) NO20052199L (en)
NZ (1) NZ539510A (en)
PL (1) PL376325A1 (en)
RS (1) RS20050318A (en)
TW (1) TW200418773A (en)
WO (1) WO2004037778A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ539432A (en) * 2002-10-21 2008-04-30 Janssen Pharmaceutica Nv Treating syndrome X with substituted tetralins and indanes
EP1554240B1 (en) * 2002-10-21 2009-05-06 Janssen Pharmaceutica N.V. Substituted tetralins and indanes and their use
AR048931A1 (en) * 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv PROCESS FOR THE PREPARATION OF SUBSTITUTED AND INDIAN TETRALIN DERIVATIVES AND PREPARATION OF SYNTHESIS INTERMEDIARIES
US20090239841A1 (en) * 2004-10-27 2009-09-24 Hutchison Alan J Diaryl Ureas as CB1 Antagonists
BRPI0620468A2 (en) 2005-12-22 2011-11-08 Transtech Pharma Inc acetic phenoxy acids as activators of delta ppar

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
EP1259494A4 (en) * 2000-02-18 2004-09-15 Merck & Co Inc Aryloxyacetic acids for diabetes and lipid disorders
EE200300140A (en) * 2000-10-05 2003-08-15 Bayer Aktiengesellschaft Propanoic acid derivatives with PPAR alpha-activating properties
AU2002222549A1 (en) * 2000-11-29 2002-06-11 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
WO2002046146A1 (en) * 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Substituted carboxylic acid derivatives
US7091225B2 (en) * 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
BR0207227A (en) * 2001-02-15 2004-02-10 Pfizer Prod Inc Ppar proliferating activated receptor compounds
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
NZ539432A (en) * 2002-10-21 2008-04-30 Janssen Pharmaceutica Nv Treating syndrome X with substituted tetralins and indanes
EP1554240B1 (en) * 2002-10-21 2009-05-06 Janssen Pharmaceutica N.V. Substituted tetralins and indanes and their use

Also Published As

Publication number Publication date
HRP20050335A2 (en) 2006-05-31
MXPA05004191A (en) 2006-01-27
TW200418773A (en) 2004-10-01
AU2003277441A1 (en) 2004-05-13
NO20052199L (en) 2005-06-24
EA200500515A1 (en) 2005-10-27
RS20050318A (en) 2007-09-21
KR20050055773A (en) 2005-06-13
BR0315596A (en) 2005-09-06
EP1569897A1 (en) 2005-09-07
AU2003277441B2 (en) 2009-05-07
WO2004037778A1 (en) 2004-05-06
PL376325A1 (en) 2005-12-27
EA009553B1 (en) 2008-02-28
JP2006503916A (en) 2006-02-02
CA2502661A1 (en) 2004-05-06
NZ539510A (en) 2008-01-31
EG24842A (en) 2010-10-13

Similar Documents

Publication Publication Date Title
CL2012001762A1 (en) Compounds derived from pyrazine, with bace inhibitory activity; pharmaceutical composition comprising them; and its use for the treatment or prevention of Alzheimer's disease or mild cognitive impairment.
UY30846A1 (en) OXINDOL DERIVATIVES REPLACED, MEDICINES THAT UNDERSTAND AND USE THEMSELVES
UY37590A (en) MODULATING COMPOUNDS OF ARYLIC HYDROCARBON RECEIVER (AhR)
CL2021000650A1 (en) Modulators of pnpla3 expression
CL2009000309A1 (en) Aromatic fluoroglycoside derivatives, pharmaceutical composition containing these compounds, procedure to prepare it and its use in the treatment of type 1 and type 2 diabetes.
UY29685A1 (en) 1,4-DIHYDROPIRIDINE-CONDENSED HETEROCICLES, PROCESSES TO PREPARE THE SAME, USE AND COMPOSITIONS CONTAINING THEM.
CL2007002384A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the treatment of psoriasis.
UY28731A1 (en) CHEMICAL COMPOUNDS
ECSP077319A (en) ACIDS 4 - ((PHENOXIALQUIL) UNCLE) -PHENOXYACETICS, AND ANALOGS OF THE SAME
CY1110326T1 (en) SUBSTITUTED TETRALINS AND INDIA AND THEIR USE
CR7795A (en) TETRALINOS AND INDANES SUBSTITUTES
ECSP077320A (en) ACIDS 4 - ((PHENOXIALQUIL) UNCLE) -PHENOXYACETICS AND ANALOGS
AR047553A1 (en) THE COMBINATION OF A SEROTONINE AND AGOMELATINE REABSORTION INHIBITOR
CL2009000599A1 (en) Compounds derived from substituted 4,5-dihydro-1h-pyrazol (4,3-g) benzothiazole; pharmaceutical composition; Useful for the treatment and prevention of cancer, infections, inflammatory and autoimmune diseases, among others.
RS20050319A (en) Treating syndrome x with substituted tetralins and indanes
UY38472A (en) FOXP3 EXPRESSION MODULATORS
CL2022003206A1 (en) Quinolone-derived compounds and their use for the treatment of cancer (div. sol. 202102501)
UY31422A1 (en) INDANO COMPOUNDS
UY31424A1 (en) 2,3-DIHIDRO-BENZOFURAN COMPOUNDS
CL2016002283A1 (en) Use of a composition comprising at least three different compounds selected from the group consisting of 5'-methylselenoadenosine, se-adenosyl-l-homocysteine, gamma-glutamyl-methylselene-cysteine, a compound of the formula (i), (ii ) or (iii) defined and a carrier to treat diabetes; composition.
AR117079A1 (en) FOXP3 EXPRESSION MODULATORS
GT200700006A (en) 1,4-DIHYDROPIRIDINE-CONDENSED HETEROCICLES, PROCESSES TO PREPARE THE SAME, USE AND COMPOSITIONS CONTAINING THEM
ECSP066628A (en) INDOL-O-GLUCOSIDS REPLACED
AR057865A1 (en) COMPOSITION OF PROANTOCIANIDIC TANINS, ITS MANUFACTURING PROCESS AND ITS APPLICATIONS
DOP2005000144A (en) POTASSIUM CHANNEL INHIBITORS

Legal Events

Date Code Title Description
FC Refusal